Thomas W. LeBlanc, MD, MA, MHS, FAAHPM, FASCO

Articles

Adverse Event Management and Patient Safety With Revumenib

January 22nd 2025

Panelists discuss the most commonly seen adverse effects (AEs) in menin inhibitor treatment, strategies for managing and mitigating these AEs to optimize outcomes, and how they compare across approved and pipeline menin inhibitors, along with best practices for clinicians to manage differentiation syndrome, a critical safety concern.

Efficacy and Potential of Revumenib in KMT2A-Translocated Leukemia

January 22nd 2025

Panelists discuss the data updates from the AUGMENT-101 trial, the potential of revumenib to reshape the treatment landscape for patients with heavily pretreated KMT2A-rearranged acute leukemia, including its observed objective response rate (ORR) and complete remission (CR)/ CR with partial recovery of peripheral blood counts (CRh) rate, and the clinical implications of revumenib in the context of bridging to stem cell transplantation.

Revumenib’s FDA Approval and Clinical Implications

January 10th 2025

Panelists discuss the FDA approval of revumenib for relapsed/refractory acute leukemia (R/R AML) with KMT2A translocation, reviewing the eligible patient population and the mechanism of action of this menin inhibitor, while exploring key findings from the AUGMENT-101 trial and how this approval may impact treatment approaches in both the R/R and broader AML settings.

Navigating Challenges in Second- and Third-Line AML Therapy

January 10th 2025

Panelists discuss how treatment goals in the second- and third-line settings for relapsed/refractory acute monocytic leukemia (R/R AML) now focus more on disease control, quality of life, and prolonging survival, and explore the most significant unmet needs in R/R AML, particularly in addressing drug resistance and optimizing therapeutic strategies.

Treatment Goals and Unmet Needs in R/R AML

January 3rd 2025

Panelists discuss how achieving responses with second-line treatment options after venetoclax-based regimens remains challenging, and explore strategies for bridging therapy to allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients who relapse post venetoclax while also addressing the evolving management of patients following transplant.

Treatment Strategies for Relapsed/Refractory AML Patients

December 20th 2024

Panelists discuss how the latest NCCN guidelines for relapsed/refractory acute monocytic leukemia (R/R AML) outline targeted therapy options outside clinical trials, and explore treatment approaches based on patient fitness, actionable biomarkers, and prior therapies, highlighting the impact of first remission duration and genetic abnormalities on treatment sequencing.